A PROSPECTIVE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITOURINARY GROUP RANDOMIZED TRIAL COMPARING TRANSURETHRAL RESECTION FOLLOWED BY A SINGLE INTRAVESICAL INSTILLATION OF EPIRUBICIN OR WATER IN SINGLE STAGE TA, T1 PAPILLARY CARCINOMA OF THE BLADDER
A PROSPECTIVE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITOURINARY GROUP RANDOMIZED TRIAL COMPARING TRANSURETHRAL RESECTION FOLLOWED BY A SINGLE INTRAVESICAL INSTILLATION OF EPIRUBICIN OR WATER IN SINGLE STAGE TA, T1 PAPILLARY CARCINOMA OF THE BLADDER
复制标题
DOI：
10.1016/s0022-5347(17)36198-0
复制
发表时间：
1993-04-01
影响因子：
6.6
通讯作者：
SYLVESTER, R
中科院分区：
文献类型：
--
作者：
OOSTERLINCK, W;KURTH, KH;SYLVESTER, R
共有431例符合条件的孤立性、原发性或复发性Ta和T1期膀胱移行细胞癌患者被纳入一项随机多中心试验，以比较80 mg单次膀胱内滴注。切除术后立即用水冲洗，观察无病期和复发率。首次复发的间隔时间明显更好，有利于epiradine组。平均随访2年后，单次表阿霉素灌注后的复发率明显降低了近一半，在所有检查的亚组中发现了相同的趋势。毒性主要限于膀胱刺激，± 10%的病例。病理学审查使T类别从T1期到Ta期发生了相当大的变化（53%）。等级的变化不太明显，但仍然很重要。
A total of 431 eligible patients with solitary, primary or recurrent stages Ta and T1 transitional cell carcinoma of the bladder was included in a randomized multicenter trial to compare a single intravesical instillation of 80 mg. epirubicin with water given immediately after resection, with respect to the disease-free interval and recurrence rate. The interval to initial recurrence was significantly better in favor of the epirubicin group. After a mean followup of 2 years it became evident that the recurrence rate after a single epirubicin instillation was decreased by nearly half with the same trend being found in all subgroups examined. Toxicity was mainly restricted to bladder irritation in plus or minus 10% of the cases. Pathology review brought considerable changes in T category from stages T1 to Ta (53%). Changes in grade were less pronounced but nevertheless important.